Cumberland Pharmaceuticals (NASDAQ:CPIX) will announce its earnings results after the market closes on Tuesday, November 13th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.09. The business had revenue of $10.16 million during the quarter, compared to analyst estimates of $9.94 million. Cumberland Pharmaceuticals had a negative return on equity of 3.12% and a negative net margin of 11.16%. On average, analysts expect Cumberland Pharmaceuticals to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of CPIX remained flat at $$6.16 during trading hours on Wednesday. The company had a trading volume of 400 shares, compared to its average volume of 18,972. The company has a quick ratio of 3.53, a current ratio of 3.96 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $82.82 million, a price-to-earnings ratio of -88.00 and a beta of 0.48. Cumberland Pharmaceuticals has a one year low of $5.06 and a one year high of $7.96.
COPYRIGHT VIOLATION NOTICE: “Cumberland Pharmaceuticals (CPIX) to Release Quarterly Earnings on Tuesday” was published by WKRB News and is the sole property of of WKRB News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/07/cumberland-pharmaceuticals-cpix-to-release-quarterly-earnings-on-tuesday.html.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.
Recommended Story: What does RSI mean?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.